vs
MainStreet Bancshares, Inc.（MNSB）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
MainStreet Bancshares, Inc.的季度营收约是REGENXBIO Inc.的1.1倍（$32.8M vs $30.3M），REGENXBIO Inc.同比增速更快（43.0% vs -8.8%），MainStreet Bancshares, Inc.自由现金流更多（$10.6M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -0.7%）
MainStreet Bancshares, Inc.是一家总部位于美国的银行控股公司，提供全面的零售及商业银行服务，涵盖存款产品、个人及商业贷款、房屋抵押贷款、财富管理方案，主要服务个人消费者、中小型企业及区域社区客户。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
MNSB vs RGNX — 直观对比
营收规模更大
MNSB
是对方的1.1倍
$30.3M
营收增速更快
RGNX
高出51.8%
-8.8%
自由现金流更多
MNSB
多$63.4M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-0.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $32.8M | $30.3M |
| 净利润 | — | $-67.1M |
| 毛利率 | 55.1% | — |
| 营业利润率 | 14.9% | -190.0% |
| 净利率 | — | -221.3% |
| 营收同比 | -8.8% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $0.46 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MNSBRGNX
| Q4 25 | $32.8M | $30.3M | ||
| Q3 25 | $33.6M | $29.7M | ||
| Q2 25 | $35.4M | $21.4M | ||
| Q1 25 | $33.9M | $89.0M | ||
| Q4 24 | $35.9M | $21.2M | ||
| Q3 24 | $34.5M | $24.2M | ||
| Q2 24 | $34.2M | $22.3M | ||
| Q1 24 | $33.3M | $15.6M |
净利润MNSBRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $4.5M | $-61.9M | ||
| Q2 25 | $4.6M | $-70.9M | ||
| Q1 25 | $2.5M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $265.0K | $-59.6M | ||
| Q2 24 | $2.6M | $-53.0M | ||
| Q1 24 | $3.3M | $-63.3M |
毛利率MNSBRGNX
| Q4 25 | 55.1% | — | ||
| Q3 25 | 54.3% | — | ||
| Q2 25 | 56.2% | — | ||
| Q1 25 | 51.5% | — | ||
| Q4 24 | 46.9% | 70.2% | ||
| Q3 24 | 47.1% | 48.8% | ||
| Q2 24 | 47.7% | 52.5% | ||
| Q1 24 | 49.4% | 72.6% |
营业利润率MNSBRGNX
| Q4 25 | 14.9% | -190.0% | ||
| Q3 25 | 16.1% | -176.3% | ||
| Q2 25 | 16.0% | -296.3% | ||
| Q1 25 | 9.2% | 13.6% | ||
| Q4 24 | -4373.3% | -242.1% | ||
| Q3 24 | 0.3% | -256.6% | ||
| Q2 24 | 8.4% | -251.3% | ||
| Q1 24 | 12.4% | -408.8% |
净利率MNSBRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | 13.4% | -208.3% | ||
| Q2 25 | 13.0% | -331.8% | ||
| Q1 25 | 7.2% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 0.8% | -246.3% | ||
| Q2 24 | 7.7% | -237.7% | ||
| Q1 24 | 9.9% | -405.4% |
每股收益（稀释后）MNSBRGNX
| Q4 25 | $0.46 | $-1.30 | ||
| Q3 25 | $0.52 | $-1.20 | ||
| Q2 25 | $0.53 | $-1.38 | ||
| Q1 25 | $0.25 | $0.12 | ||
| Q4 24 | $-2.19 | $-0.99 | ||
| Q3 24 | $-0.04 | $-1.17 | ||
| Q2 24 | $0.27 | $-1.05 | ||
| Q1 24 | $0.36 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $218.6M | $102.7M |
| 总资产 | $2.2B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MNSBRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益MNSBRGNX
| Q4 25 | $218.6M | $102.7M | ||
| Q3 25 | $218.4M | $161.5M | ||
| Q2 25 | $213.5M | $213.7M | ||
| Q1 25 | $209.6M | $274.2M | ||
| Q4 24 | $208.0M | $259.7M | ||
| Q3 24 | $226.1M | $301.4M | ||
| Q2 24 | $224.7M | $348.3M | ||
| Q1 24 | $223.1M | $390.7M |
总资产MNSBRGNX
| Q4 25 | $2.2B | $453.0M | ||
| Q3 25 | $2.1B | $525.2M | ||
| Q2 25 | $2.1B | $581.0M | ||
| Q1 25 | $2.2B | $490.9M | ||
| Q4 24 | $2.2B | $466.0M | ||
| Q3 24 | $2.2B | $519.1M | ||
| Q2 24 | $2.1B | $569.4M | ||
| Q1 24 | $2.1B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.8M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $10.6M | $-52.8M |
| 自由现金流率自由现金流/营收 | 32.5% | -174.0% |
| 资本支出强度资本支出/营收 | 12.7% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $14.9M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流MNSBRGNX
| Q4 25 | $14.8M | $-52.3M | ||
| Q3 25 | $5.6M | $-56.0M | ||
| Q2 25 | $1.2M | $-49.3M | ||
| Q1 25 | $1.5M | $33.6M | ||
| Q4 24 | $14.7M | $-31.6M | ||
| Q3 24 | $4.5M | $-40.5M | ||
| Q2 24 | $1.2M | $-45.5M | ||
| Q1 24 | $3.6M | $-55.5M |
自由现金流MNSBRGNX
| Q4 25 | $10.6M | $-52.8M | ||
| Q3 25 | $5.5M | $-56.5M | ||
| Q2 25 | $-2.6M | $-49.7M | ||
| Q1 25 | $1.4M | $32.6M | ||
| Q4 24 | $13.8M | $-32.7M | ||
| Q3 24 | $4.3M | $-40.9M | ||
| Q2 24 | $1.1M | $-46.0M | ||
| Q1 24 | $3.0M | $-56.0M |
自由现金流率MNSBRGNX
| Q4 25 | 32.5% | -174.0% | ||
| Q3 25 | 16.2% | -189.9% | ||
| Q2 25 | -7.4% | -232.8% | ||
| Q1 25 | 4.1% | 36.6% | ||
| Q4 24 | 38.5% | -154.2% | ||
| Q3 24 | 12.5% | -168.9% | ||
| Q2 24 | 3.1% | -206.2% | ||
| Q1 24 | 9.1% | -358.5% |
资本支出强度MNSBRGNX
| Q4 25 | 12.7% | 1.7% | ||
| Q3 25 | 0.4% | 1.7% | ||
| Q2 25 | 10.8% | 1.8% | ||
| Q1 25 | 0.2% | 1.2% | ||
| Q4 24 | 2.5% | 5.1% | ||
| Q3 24 | 0.5% | 1.3% | ||
| Q2 24 | 0.3% | 2.1% | ||
| Q1 24 | 1.8% | 3.6% |
现金转化率MNSBRGNX
| Q4 25 | — | — | ||
| Q3 25 | 1.24× | — | ||
| Q2 25 | 0.26× | — | ||
| Q1 25 | 0.59× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 16.87× | — | ||
| Q2 24 | 0.45× | — | ||
| Q1 24 | 1.10× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MNSB
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
